Literature DB >> 11149897

Purines inhibit poly(ADP-ribose) polymerase activation and modulate oxidant-induced cell death.

L Virág1, C Szabó.   

Abstract

Purines such as adenosine, inosine, and hypoxanthine are known to have potent antiinflammatory effects. These effects generally are believed to be mediated by cell surface adenosine receptors. Here we provide evidence that purines protect against oxidant-induced cell injury by inhibiting the activation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP). Upon binding to broken DNA, PARP cleaves NAD+ into nicotinamide and ADP-ribose and polymerizes the latter on nuclear acceptor proteins such as histones and PARP itself. Overactivation of PARP depletes cellular NAD+ and ATP stores and causes necrotic cell death. We have identified some purines (hypoxanthine, inosine, and adenosine) as potential endogenous PARP inhibitors. We have found that purines (hypoxanthine > inosine > adenosine) dose-dependently inhibited PARP activation in peroxynitrite-treated macrophages and also inhibited the activity of the purified PARP enzyme. Consistently with their PARP inhibitory effects, the purines also protected interferon gamma + endotoxin (IFN/LPS) -stimulated RAW macrophages from the inhibition of mitochondrial respiration and inhibited nitrite production from IFN/LPS-stimulated macrophages. We have selected hypoxanthine as the most potent cytoprotective agent and PARP inhibitor among the three purine compounds, and investigated the mechanism of its cytoprotective effect. We have found that hypoxanthine protects thymocytes from death induced by the cytotoxic oxidant peroxynitrite. In line with the PARP inhibitory effect of purines, hypoxanthine has prevented necrotic cell death while increasing caspase activity and DNA fragmentation. As previously shown with other PARP inhibitors, hypoxanthine acted proximal to mitochondrial alterations as hypoxanthine inhibited the peroxynitrite-induced mitochondrial depolarization and secondary superoxide production. Our data imply that purines may serve as endogenous PARP inhibitors. We propose that, by affecting PARP activation, purines may modulate the pattern of cell death during shock, inflammation, and reperfusion injury.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11149897     DOI: 10.1096/fj.00-0299com

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  29 in total

1.  Mapping hypoxia-induced bioenergetic rearrangements and metabolic signaling by 18O-assisted 31P NMR and 1H NMR spectroscopy.

Authors:  Darko Pucar; Petras P Dzeja; Peter Bast; Richard J Gumina; Carmen Drahl; Lynette Lim; Nenad Juranic; Slobodan Macura; Andre Terzic
Journal:  Mol Cell Biochem       Date:  2004 Jan-Feb       Impact factor: 3.396

2.  Regulation of mitochondrial poly(ADP-Ribose) polymerase activation by the β-adrenoceptor/cAMP/protein kinase A axis during oxidative stress.

Authors:  Attila Brunyanszki; Gabor Olah; Ciro Coletta; Bartosz Szczesny; Csaba Szabo
Journal:  Mol Pharmacol       Date:  2014-07-28       Impact factor: 4.436

Review 3.  Natural inhibitors of poly(ADP-ribose) polymerase-1.

Authors:  Marek Banasik; Todd Stedeford; Robert P Strosznajder
Journal:  Mol Neurobiol       Date:  2012-04-04       Impact factor: 5.590

4.  The novel inosine analogue INO-2002 exerts an anti-inflammatory effect in a murine model of acute lung injury.

Authors:  Jon G Mabley; Pal Pacher; Kanneganti G K Murthy; William Williams; Garry J Southan; Andrew L Salzman; Csaba Szabo
Journal:  Shock       Date:  2009-09       Impact factor: 3.454

5.  The novel inosine analogue, INO-2002, protects against diabetes development in multiple low-dose streptozotocin and non-obese diabetic mouse models of type I diabetes.

Authors:  Jon G Mabley; Pal Pacher; Kanneganti G K Murthy; William Williams; Garry J Southan; Andrew L Salzman; Csaba Szabo
Journal:  J Endocrinol       Date:  2008-06-18       Impact factor: 4.286

6.  Cytoprotective effects of adenosine and inosine in an in vitro model of acute tubular necrosis.

Authors:  Katalin Módis; Domokos Gero; Nóra Nagy; Petra Szoleczky; Zoltán Dóri Tóth; Csaba Szabó
Journal:  Br J Pharmacol       Date:  2009-11       Impact factor: 8.739

7.  Inosine protects against the development of diabetes in multiple-low-dose streptozotocin and nonobese diabetic mouse models of type 1 diabetes.

Authors:  Jon G Mabley; Alex Rabinovitch; Wilma Suarez-Pinzon; György Haskó; Pál Pacher; Robert Power; Gary Southan; Andrew Salzman; Csaba Szabó
Journal:  Mol Med       Date:  2003 Mar-Apr       Impact factor: 6.354

8.  Effects of inosine on reperfusion injury after cardiopulmonary bypass.

Authors:  Gábor Veres; Tamás Radovits; Leila Seres; Ferenc Horkay; Matthias Karck; Gábor Szabó
Journal:  J Cardiothorac Surg       Date:  2010-11-08       Impact factor: 1.637

9.  Inhibition of caspase-mediated PARP-1 cleavage results in increased necrosis in isolated islets of Langerhans.

Authors:  Reid Aikin; Lawrence Rosenberg; Steven Paraskevas; Dusica Maysinger
Journal:  J Mol Med (Berl)       Date:  2004-04-23       Impact factor: 4.599

Review 10.  Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

Authors:  Nicola J Curtin; Csaba Szabo
Journal:  Mol Aspects Med       Date:  2013-01-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.